Teva slips as 2025 earnings outlook misses estimates
Teva Pharmaceutical (TEVA) stock falls as the generic drugmaker with its Q4 2024 results set its 2025 earnings outlook below ...
Time To Be Bullish On Sanofi Ahead Of Its Earnings
Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...
Sanofi (NASDAQ:SNY) Shares Sold by Geneos Wealth Management Inc.
Geneos Wealth Management Inc. decreased its position in Sanofi (NASDAQ:SNY – Free Report) by 2.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 10,223 shares of the company’s stock ...
Fifth Third Bancorp Has $1.23 Million Stock Holdings in Sanofi (NASDAQ:SNY)
Fifth Third Bancorp reduced its stake in Sanofi (NASDAQ:SNY – Free Report) by 9.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange ...
Sanofi Expected to Report Lower Sales, Profit; Size of Buyback in Focus -- Earnings Preview
BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara ...
FierceBiotech1d
Atalanta loads crossbow with $97M, targeting neuro trial starts for 2 RNAi therapies
Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...
Sanofi’s Promising Future: Buy Rating Backed by Strategic Moves and Strong Pipeline
Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Risinger from ...
Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...
How Is The Market Feeling About Sanofi?
Sanofi's SNY +1.27% + Free Alerts short percent of float has risen 11.76% since its last report. The company recently ...
J.P. Morgan Sticks to Their Hold Rating for Sanofi (SNYNF)
J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €105.00. The ...
San Francisco Examiner5d
FDA Warns Sanofi of Manufacturing Irregularities at Key Facility
The U.S. Food and Drug Administration has warned the pharmaceutical company Sanofi about significant deviations from Current ...
Benzinga.com20d
Sanofi's Blood Cancer Drug's New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma
Also Read: Sanofi’s 340B Credit Proposal Draws Federal Warning For Statutory Violation Key secondary endpoints were also achieved, including very good partial response, the incidence rate of ...